As part of the detailed agenda, Ipsos’ Reena Sangar will moderate a virtual panel discussion about market strategies and debate on accessibility of digital therapeutics (November 17th).
Digital therapeutics (DTx), a subset of digital health, are evidence-based therapeutic interventions driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. Digital therapeutic companies should publish trial results inclusive of clinically meaningful outcomes in peer-reviewed journals. Treatments are being developed for the prevention and management of a wide variety of diseases and conditions, including type II diabetes, congestive heart failure, obesity, Alzheimer's disease, dementia, asthma, substance abuse, ADHD, hypertension, anxiety, depression, and several others. This talk will discuss current go-to-market strategies, examples of how DTx are being deployed and debate how the models are commercially working. The speakers will also debate the level of accessibility the products provide to margalinalized groups, and whether DTx helps or harms health equity goals.
For more about this conference, please click here.
Reena Sangar, Global Head, Connected Health, Ipsos